RESEARCH ARTICLE


COL1A1 Gene Expression in Hepatitis B Virus (HBV) Related Hepatocellular Carcinoma (HCC) Egyptian's Patients



Amal A. Mohamed1, Yousry Esam-Eldin Abo-Amer2, Amyan Aalkhalegy3, Lamiaa Abdelfattah Fathalla4, Mostafa Bedair Elmaghraby5, Mohamed Mahmoud Elhoseeny6, Sahar Mohamed Mostafa7, Mohamed El-Abgeegy7, Rania Abdelmonem Khattab8, Dalia Ali El-damasy9, Wafaa Salah10, Abeer Mohammed Salem11, Wael Mohamed Elmashad12, Mohamed Elbahnasawy13, Sherief Abd-Elsalam14, *
1 Department of Biochemistry, National Hepatology Tropical Medicine Research Institute, Cairo, Egypt
2 Department of Gastroenterology and Infectious Diseases, Hepatology, Mahala Hepatology Teaching Hospital, Gharbiya, Egypt
3 Department of Surgery, Amyan Aalkhalegy, Al Sahel Teaching hospital, Cairo, Egypt
4 Clinical Pathology, National Cancer Institute, Cairo University, Giza, Egypt
5 Department of Gastrointestinal and Hepatobiliary Surgery, Mahala Hepatology Teaching Hospital, Gharbiya, Egypt
6 Mahalla Teaching Liver Hospital, Gharbiya, Egypt
7 Department of Liver Transplantation, National Hepatology and Tropical Medicine Research Inistitue, Cairo, Egypt
8 Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
9 Department of Microbioogy, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt
10 Department of Internal Medicine, National Institute of Diabetes and Endocrinology, Cairo, Egypt
11 Department of Internal Medicine, KasrAlainy, Faculty of Medicine, Cairo University, Cairo, Egypt
12 Department of Physiology, Tanta University, Tanta, Egypt
13 Department of Emergency Medicine and Traumatology, Tanta University, Tanta, Egypt
14 Department of Tropical Medicine and Infectious Diseases, Tanta University, Tanta, Egypt

Article Information


Identifiers and Pagination:

Year: 2021
Volume: 11
First Page: 108
Last Page: 114
Publisher ID: TOBIOMJ-11-108
DOI: 10.2174/1875318302111010108

Article History:

Received Date: 15/3/2021
Revision Received Date: 28/7/2021
Acceptance Date: 26/8/2021
Electronic publication date: 20/12/2021
Collection year: 2021

Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 1775
Abstract HTML Views: 810
PDF Downloads: 421
ePub Downloads: 321
Total Views/Downloads: 3327
Unique Statistics:

Full-Text HTML Views: 740
Abstract HTML Views: 400
PDF Downloads: 279
ePub Downloads: 186
Total Views/Downloads: 1605



Creative Commons License
© 2021 Mohamed et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El-Giash Street 31527, Tanta, Egypt; Tel: +2-01224608774; E-mail: sherif.abdelbaky@med.tanta.edu.eg


Abstract

Introduction:

Collagens are the most abundant proteins in the human body, accounting for one-third of total proteins. Over the last few years, accumulated evidence have indicated that some collagens are differentially expressed in cancer. The aim of the study was to assess COL1A1 gene expression as a novel marker for the progression of hepatitis B cirrhosis into hepatocellular carcinoma.

Methods:

This cohort study included 348 subjects and was conducted between May 2018 and June 2019. Subjects were divided into 4 groups: group1 included HBV positive hepatocellular carcinoma patients “HCC” (n= 87), group II included HBV positive patients with liver cirrhosis “LC” (n = 87), group III included chronic hepatitis B patients with neither HCC nor cirrhosis “ C-HBV” (n = 87) and group IV consisted of healthy volunteers as controls (n = 87). Fasting venous blood samples (10 ml) were collected from each participant in this study and were used for assessment of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin and alfa-fetoprotein (AFP). Another portion of blood was collected in 2 vacutainer tubes containing EDTA, one for Complete blood count and the other for gene expression of COL1A1.

Results:

The gene expression of collagen was 6.9 ± 8.8 in group 1 (HBV positive hepatocellular carcinoma patients) and this was a significant increase in comparison with the other groups. In group 2 (HBV positive patients with liver cirrhosis), the gene expression (collagen) was 3.7±1.5 and it was significantly increased when compared with group 4 (healthy volunteers).

Conclusion:

COL1A1 gene expression can be used as an indicator of the progression of hepatitis B cirrhosis into hepatocellular carcinoma.

Keywords: Hepatocellular carcinoma, HCC, HBV, Collagen, Gene, Cirrhosis.

1. INTRODUCTION

Hepatocellular Carcinoma (HCC) is one of the causes of death all over the world [1]. It is the third lethal type of cancer, causing around 600,000 deaths per year [2]. It represents the sixth most common cancer worldwide, and in Egypt, it represents the fourth [3]. It is a sequela of diverse causes of liver damage as chronic hepatitis C and B infection, chronic use of alcohol as well as nonalcoholic steatohepatitis [4] (EASL guidelines, 2018).

Chronic Hepatitis C virus (HCV) infection represents 75% to 85% of the HCV-infected patients, and nearly 20% of them will later develop complications like cirrhosis or HCC after 20 years of infection [5]. Although liver resection and transplantation are the most common treatments for HCC, high rates of recurrence and metastasis lead to poor prognosis. Therefore, early diagnosis and treatment of HCC are essential [6]. Hepatitis B is also a life-threatening liver infection due to the aggressive transformation to liver cirrhosis and HCC. The WHO previously reported Egypt an area of endemicity of intermediate degree (2%-7%) regarding HBV [7].

Collagens are the most abundant proteins in the human body, accounting for one-third of total proteins. In humans, there are at least 28 different types of collagen proteins encoded by 44 collagen genes [8]. They are essential in the extracellular matrix (ECM), which is the major component in the tumor microenvironment and can regulate tumor cell behaviors [9, 10]. Collagen proteins are produced and secreted by fibroblasts [11], osteoblasts [12], hematopoietic cells [13], and also can be biosynthesized and regulated by endothelial cells [14, 15] and cancer cells [16]. Over the last few years, accumulated evidence-have indicated that some collagens are differentially expressed in cancer. Collagen type I contributes to pancreatic, lung, bladder, liver and breast cancer progression [17-19], as it enhances the tumor cell proliferation and the epithelial-mesenchymal transition of HCC [20].

Collagen type I alpha 1 (COL1A1) gene encodes the pro-alpha 1 chains of type I collagen whose triple helix comprises two alpha 1 chains and one alpha 2 chain [21]. Type I collagen is a fibril-forming collagen, and the 3D type I collagen-rich culture is a common method to investigate the proliferation and/or metastasis of cancers [22]. Previous studies have suggested that COL1A1 is a candidate survival-related factor in hepatocellular carcinoma [23]. Collagen is also considered an important substance seen in liver fibrosis, especially collagen type IV, which is available as a marker of hepatitis C fibrosis. Collagen types I, II, and III have also been reported to be associated with the liver fibrosis stage of chronic HCV [23].

COL1A1 promotes Slug-dependent epithelial-to-mesenchymal transition, thereby enhancing the invasion and metastasis of HCC [24]. Recently, abnormal expression levels of COL1A1 and COL1A2 have been reported in several types of cancer [25]. COL1A1 and COL1A2 mRNA expression levels are upregulated in colorectal cancer and \\medulloblastoma. COL1A1 and COL1A2 were deferentially expressed in gastric cancer and predicted poor clinical outcomes in gastric cancer patients [26, 27].

2. MATERIALS AND METHODS

2.1. The Setting, Study Design

This cohort study included 348 subjects and was conducted between May 2018 and June 2019 in Tanta University Hospital and the National hepatology and tropical medicine research institute. The study was approved by the institutional ethical committee. Subjects were divided into 4 groups: group 1 included HBV positive hepatocellular carcinoma patients “HCC” (n= 87), group II included HBV positive patients with liver cirrhosis “LC” (n = 87), group III included chronic hepatitis B patients with neither HCC nor cirrhosis “C-HBV” (n = 87) and group IV of healthy volunteers as controls (n = 87).

For all subjects, complete medical history and physical examination were done, and body mass index (BMI) was calculated. All patients were positive for HBV, confirmed by hepatitis B surface antigen (HBsAg) and HBV PCR (Qiagen, MX 3000 applied biosystem). All subjects were confirmed as HCV negative by screening for Anti-HCV using a commercially available immunoassay (HCV Murex AB, Diasorin, Saluggia, Vercelli, Italy).

For HCC patients and LC patients, the liver status was estimated by Model for End-Stage Liver Disease (MELD) score and Updated MELD (U MELD) score. HCC patients were staged according to Okuda staging, Cancer of the Liver Italian Program (CLIP) staging and Vienna survival model for HCC (VISUM-HCC).

Study exclusion criteria were: previous cancer, current cancer apart from HCC cancer, history of alcohol abuse, renal insufficiency, proteinuria, suspected infections, clinically overt diabetes mellitus, thyroid dysfunction, or any other endocrine disorder, and hormone or thyroid regulatory medication intake. Informed consent was obtained from all participating subjects before the study. All participants gave their written informed consent prior to inclusion.

2.2. Blood Sampling and Biochemical Assays

Fasting venous blood samples (10 ml) were collected from each participant in this study. A portion of blood was left to clot and then centrifuged at 3500 g for 5 min to separate the serum used for assessment of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin and alfa-fetoprotein (AFP). Another portion of blood was collected in 2 vacutainer tubes containing EDTA, one for Complete blood count and the other for gene expression of COL1A1.

2.2.1. RNA Extraction

Peripheral Blood Mononuclear Cells (PBMCs) were separated using Ficoll density centrifugation and sedimentation. RNA was separated from PBMCs using QIAamp viral RNA extraction kit (QIAGEN GmbH, Hilden, Germany).

2.2.2. Quantification of COL1A1

Gene expression of COL1A1 was performed using TaqMan Expression (Applied Biosystems Inc, Foster City, CA, USA). β-actin was the reference gene for each sample. Fractional threshold cycles (CT) expressed the initial concentration of the target sequence. Relative mRNA quantification was calculated using the arithmetic formula 2 –ΔC T, where ΔCT is the difference between the CT of a given target cDNA and an endogenous reference cDNA. Thus, this value yielded the amount of the target normalized to an endogenous reference [28].

2.3. Statistical Analysis

The collected data were tabulated and analyzed using SPSS version 20 software (SPSS Inc, Chicago, ILL Company). Categorical data were presented as numbers and percentages, while quantitative data were expressed as mean ±standard deviation. Chi-square (X2) test, Fisher's exact test, ANOVA, and Pearson’s correlation coefficient (r) were used as tests of significance. Significant ANOVA was followed by the Bonferroni test to detect significant pairs. ROC curve was used to determine the cutoff value of collagen with optimum sensitivity and specificity in early diagnosis of HCC. The accepted level of significance in this work was stated at 0.05 (P <0.05 was considered significant) [29].

3. RESULTS

The clinical characteristics of the included subjects are shown in Table 1, 64.4% (n = 56) were male. Smoking-induced liver disease was the most frequent underlying cause of HCC in 59.8% (n = 52).

Serum levels of collagen were measured in each of the 4 groups. The comparison showed marked differences in collagen-related measures (Table 2). It was found to be significantly increased in HBV patients (2.4 ± 1.8 ng/ml), cirrhotic patients (3.7±1.5 ng/ml) and HCC patients (6.9±8.8ng/ml) in comparison to healthy subjects (1.7±4.5 ng/ml).

Table 1. Demographic and clinical data of the studied groups.
I- HCC (87) II- Cirrhosis Group (87) III-HBV Group (87) IV-Control (87) P Value
No % No % No % No %
Sex Female 31 35.6 46 52.9 29 33.3 33 37.9 8.5(0.04*)
Male 56 64.4 41 47.1 58 66.7 54 62.1
HBVsAg Negative 0 0 0 0 0 0 87 100 348(.000*)
Positive 87 100 87 100 87 100 0 0
HCV ab Negative 87 100 87 100 87 100 87 100.0 -
Positive 0 0 0 0 0 0 0 0
Alcohol No 86 98.9 78 89.7 76 87.4 87 100.0 18.8(.000*)
Yes 1 1.1 9 10.3 11 12.6 0 0
Smoking No 35 40.2 81 93.1 48 55.2 87 100 109(.000*)
Yes 52 59.8 6 6.9 39 44.8 0 0
HBV: hepatitis B virus HCV: Chronic Hepatitis C virus
Table 2. Comparison between different studied groups regarding clinical data, viral load & COL1A1 Gene Expression.
- I-HCC (87) II-cirrhosis Group (87) III-HBV Group (87) IV-Control (87) P Value
Age 61.17±9.4 55.8±10 38.3±8.5 43.2±15.5 78.4(.000*)
ALT 63.08± 33.8# (III, IV) 53.6±57.9# (III, IV) 79.4±29.9 30.3±5.6# (I, II, III) 27(.000*)
AST 103.4±65# (III, IV) 81.8±119.6# (IV) 67.4±30.9#(I, IV) 33.2±7.6 15.5(.000*)
Total bilirubin 4.5±4.9# (III, IV) 4.9±5.8# (III, IV) 1.1±0.4 0.76±0.2 28.5(.000*)
INR 1.5±.3034# (3,4) 1.5±0.8# (3,4) 1.1±0.3 0.98±0.07 29.7(.000*)
Albumin 2.614± 0.5# (III, IV) 2.5±0.8#(III, IV) 3.6±0.6 3.9±0.2 130.6(.000*)
ALP 170.6±117.5 156.3±110.828 - - 0.8(>0.05)
AFP 2846.9±1342.2# (II, IV) 208.2±143.4 - 5.7±1.7 17.3(.000*)
Serum creatinine 2.15±1.7# (II, III, IV) 1.6±1.2# (II, III, IV) 1.023±0.3713#(III) 0.9±0.16 24.5(.000*)
Hb 11.190± 1.7 10.6±2# (I, III) 12±1.8 - 12.4(.000*)
WBCS 1476± 232.6 7.6±5.5 8034.5 ±1382.5# (II, I) - 1333(.000*)
Platelets 118.414±53.2647 137±70.3 294.8±75.3# (II, I) - 182.2(.000*)
Meld 20.4±9 18.1±9.3 - - 1.6(>0.05)
U meld 4.140±1 3.9±1.3 - - 1.3(>0.05)
PV 1.2±0.4 - - - -
Temp 37.3±0.5 - - - -
Pulse 85.09± 6.2 - - - -
BMI 26.06±2.2 30.7±2.2 30.3±4.7#(I,IV) 22.5±3.6 117.9(.000*)
Okuda stage 2.32±0.7 - - - -
Okuda score 2.2±1.3 - - - -
Clip stage 2.3±0.6 - - - -
Clip score 2.9± 1.6 - - - -
Tokyo score 5.2±1.6 - - - -
Visme HCC viena stage 1.7±0.8 - - - -
SME HCC Viena score 2.4±1.4 - - - -
Size 4.74±2.548 - - - -
HBV DNA 3551.3± 2023.1 3383.6±1448.8 1455078694.3±6525410985.2#(I,II) - 4.3(0.02*)
Gene expression (collagen) 6.9 ±8.8# (II,IIII,IV) 3.7±1.5# (IV) 2.4±1.8 1.7±4.5 18.5(.000*
*Significant results & # significant pairs, values are expressed as Mean ± standard error of mean (SEM). AST: aspartat aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, PLT: platelets count, and AFP: alpha fetoprotein international normalized ratio (INR), Hb: Haemoglobin.

The collagen levels were higher in HCC and LC patients as compared with the other 2 groups. Moreover, the increase of collagen levels was also statistically significant between both HCC and LC patients and CH-B patients, and between HCC and LC patients, as shown in Fig. (1).

The Receiver Operating Characteristic (ROC) curve was used to determine the cut-off value of collagen for predicting the development of HCC in HBV-positive patients with liver cirrhosis. The area under the ROC curve (AUC) was 0.529, indicating a fair predictive power for hepatic cancer (Fig. 2).

Fig. (1). Collagen expression in different clinical stages in study patients.

Fig. (2). ROC curve for collagen level to establish the optimal cut-off values for the prediction of the development of HCC.

4. DISCUSSION

HCC is one of the sequelae of liver damage due to chronic hepatitis C and B infection [29-42]. COL1A1 is a candidate survival-related factor in hepatocellular carcinoma, which was proved to enhance the invasion and metastasis of the neoplasm [10].

In this study, there were 3 groups of HBV-positive patients compared to the 4th group of healthy controls. The gene expression of collagen was 6.9 ± 8.8 in group 1 (HBV positive hepatocellular carcinoma patients), and this was a significant increase in comparison with the other groups. In group 2 (HBV positive patients with liver cirrhosis), the gene expression (collagen) was 3.7±1.5, and it was significantly increased when compared with group 4 (healthy volunteers).

ROC curve was made to detect the optimal cut-off value for predicting the occurrence of hepatocellular carcinoma, and it was found that the COL1A1 gene expression of ≥ 5.6 has a fair predictive power, which can predict the presence of HCC with 61.5% sensitivity and 40% specificity and 95% Confidence Interval.

These results are concordant with Ma et al. as well as Lin et al., who found that COL1A1 is extremely expressed in Hepatocellular carcinoma and deliberates substantial survival disadvantage, and that upregulated COL1A1 expression at both mRNA and protein levels strongly correlates with Hepatocellular carcinoma evolution [24, 30]. Also, Hayashi et al. found that the COL1A1 was highly expressed in cases of liver cirrhosis as well as HCC compared to the healthy population [23].

On the other hand, Hayashi et al. found that there was a small group of HCC that has down-regulated mRNA expression mainly due to promoter methylation, and these cases were correlated with poor overall survival. In these cases, the single nucleotide polymorphism array displayed no chromosomal deletion in the locus of COL1A1. Importantly, the methylation value in the tumor tissue was higher than that of the adjacent liver tissue [23].

Moreover, due to the epigenetic modifications, there are different expressions of COL1A1 in different tumors. Frequent promoter methylation was found in renal cell carcinoma [31], and there was a decreased expression in ovarian serous carcinoma [32].

It is consistent with recent conclusions that showed COL1A1 was highly expressed in human breast cancer. Additionally, COL1A1 mRNA levels are significantly elevated in gastric cancer tissues when compared to normal ones, and lower expression levels of COL1A1 are powerfully connected with improved survival in patients with gastric cancer [33].

Moreover, like our results, Zhao et al. found that the frequency of COL1A1 polymorphism was higher in cirrhotic patients as compared to healthy people. This was accompanied by higher transcriptional activity and a high possibility of association with liver fibrogenesis. But they did not investigate the marker in HCC [34]. Sun et al. studied the COL1A1 gene polymorphism in HCC and reported an association with a reduced COL1A1 mRNA expression which was significantly correlated with capsule formation in patients with HCC [23, 34, 35]. However, in our patients, we studied the gene expression rather than the polymorphism in the whole cancer group rather than a capsulated group.

CONCLUSION

In conclusion, COL1A1 gene expression can be used as an indicator of the progression of hepatitis B cirrhosis into hepatocellular carcinoma, and further studies are required on a large sample size.

Another study reported the expression of COL1A1, COL1A2, COL3A1 in blood and could be applied as predictive biomarkers in lung adenocarcinoma [36], which indicates the important role of this gene in many diseases.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was approved by the Research Ethics Committee of Tanta University Faculty of Medicine, Tanta, Egypt with approval number: 30431/11/18.

HUMAN AND ANIMAL RIGHTS

No animals were used in this research. All human research procedures were followed in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.

CONSENT FOR PUBLICATION

All participants gave their written informed consent prior to inclusion.

AVAILABILITY OF DATA AND MATERIALS

Datasets used and/or analysed during the current study are available from the corresponding author [S.A.] on reasonable request.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Gupta H, Youn GS, Shin MJ, Suk KT. Role of gut microbiota in hepatocarcinogenesis. Microorganisms 2019; 7(5): 121.
[2] Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017; 8(4): 343-9.
[3] Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017; 3(12): 1683-91.
[4] Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69(1): 182-236. [Erratum in: J Hepatol. 2019 Apr;70]. [4]. [:817. PMID: 29628281].
[5] Josep Q, Rodríguez F, Gregori J, et al. Primers and methods for detecting human hepatitis C virus (HCV) variants in an isolated sample 2019.
[6] Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2018; 33(2): 347-54.
[7] Mohamed AA, Abdo S, Said E, et al. Serum vitamin D levels in chronic hepatitis B patients before and during treatment. Infect Disord Drug Targets 2020; 20(6): 840-7.
[8] Thangavelu PU, Krenács T, Dray E, Duijf PH. In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion. Clin Epigenetics 2016; 8: 120.
[9] Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61(2): 198-223.
[10] Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumour Biol 2014; 35(4): 2871-82.
[11] Alex L, Frangogiannis NG. The cellular origin of activated fibroblasts in the infarcted and remodeling myocardium 2018.
[12] Hosaki-Takamiya R, Hashimoto M, Imai Y, et al. Collagen production of osteoblasts revealed by ultra-high voltage electron microscopy. J Bone Miner Metab 2016; 34(5): 491-9.
[13] Buchtler S, Grill A, Hofmarksrichter S, et al. Cellular origin and functional relevance of collagen I production in the kidney. J Am Soc Nephrol 2018; 29(7): 1859-73.
[14] Wang H, Su Y. Collagen IV contributes to nitric oxide-induced angiogenesis of lung endothelial cells. Am J Physiol Cell Physiol 2011; 300(5): C979-88.
[15] Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 2009; 20(7): 1471-9.
[16] Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med 2019; 17(1): 309.
[17] Brooks M, Mo Q, Krasnow R, et al. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget 2016; 7(50): 82609-19.
[18] Barcus CE, O’Leary KA, Brockman JL, et al. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res 2017; 19(1): 9.
[19] Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol 2008; 38(1): 95-104.
[20] Zhang R, Ma M, Lin XH, et al. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment. BMC Cancer 2018; 18(1): 901.
[21] Prockop D. Mutations that alter the primary structure of type I collagen. Bio Chem 1990; 265(26): 15349-52.
[22] Dudley DT, Li X-Y, Hu CY, Kleer CG, Willis AL, Weiss SJ. A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc Natl Acad Sci USA 2014; 111(41): 14882-7.
[23] Hayashi M, Nomoto S, Hishida M, et al. Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma. BMC Cancer 2014; 14: 108.
[24] Ma HP, Chang HL, Bamodu OA, et al. Collagen 1A1 (COL1A1) is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis. Cancers (Basel) 2019; 11(6): 786.
[25] Lin P, Tian P, Pang J, et al. Clinical significance of COL1A1 and COL1A2 expression levels in hypopharyngeal squamous cell carcinoma. Oncol Lett 2020; 20(1): 803-9.
[26] Li J, Ding Y, Li A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J Surg Oncol 2016; 14(1): 297.
[27] Liu X, Wu J, Zhang D, et al. Identification of potential key genes associated with the pathogenesis and prognosis of gastric cancer based on integrated bioinformatics analysis. Front Genet 2018; 9: 265.
[28] Kataki K, Borthakur P, Kumari N, Deka M, Kataki AC, Medhi S. Association of mRNA expression of toll-like receptor 2 and 3 with hepatitis B viral load in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. J Med Virol 2017; 89(6): 1008-14.
[29] IBM SPSS Statistics for Windows, version 20 2017.
[30] Lin ZY, Chuang WL. Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother 2012; 66(6): 454-8.
[31] Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006; 66(10): 5021-8.
[32] Quinn MC, Wojnarowicz PM, Pickett A, et al. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol 2013; 42(3): 912-20.
[33] Meng C, He Y, Wei Z, et al. MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. Biomed Pharmacother 2018; 104: 718-28.
[34] Zhao YP, Wang H, Fang M, Ji Q, Yang ZX, Gao CF. Study of the association between polymorphisms of the COL1A1 gene and HBV-related liver cirrhosis in Chinese patients. Dig Dis Sci 2009; 54(2): 369-76.
[35] Sun W, Zhang Y, Liu B, Duan Y, Li W, Chen J. Gene polymorphism of MUC15, MMP14, BRAF, and COL1A1 is associated with capsule formation in hepatocellular carcinoma Can J Gastroenterol Hepatol 2021; 2021: 9990305.
[36] Chen J, Chen S, Wang F, Wang S. COL1A1, COL1A2, COL3A1 and DCN are Potential Biomarkers to Predict Progression from Smokers to Suffering from Lung Adenocarcinoma Adenocarcinoma Researchsquare 2020.
[37] Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017; 29(3): 317-21.
[38] Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res 2017; 11(2): OC32-4.
[39] Abdelfattah AAM, Rizk F, Hawash N, Hanafy A, El-Kalla F, Abd-Elsalam S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int J Hyperthermia 2018; 34(8): 1367-71.
[40] El-Gebaly F, Abou-Saif S, Elkadeem M, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in egyptian patients. Curr Cancer Drug Targets 2019; 19(11): 896-905.
[41] Badawi R, Soliman H, Ziada D, et al. Serum markers as a predictor of hepatic fibrosis compared to fibroscan in chronic hepatitis B Infected egyptian patients: A cross-sectional study. Open Biomark J 2020; 10: 69-75.
[42] Mohamed AA, El-Toukhy N, Ghaith DM, et al. Talin-1 gene expression as a tumor marker in hepatocellular carcinoma patients: A pilot study. Open Biomark J 2020; 10: 15-22.